Paradiso A, Tommasi S, Brandi M, Marzullo F, Simone G, Lorusso V, Mangia A, De Lena M
Division of Medical Oncology, Oncology Institute, Bari, Italy.
Cancer. 1989 Nov 1;64(9):1922-7. doi: 10.1002/1097-0142(19891101)64:9<1922::aid-cncr2820640927>3.0.co;2-i.
The biological and prognostic role of hormone receptor status and proliferative activity have been studied in two series of patients affected by inflammatory breast carcinoma (IBC, 28 patients) and locally advanced breast cancer (LABC, 50 patients). Estrogen receptor (ER) and progesterone receptor (PgR) were measured by dextran-coated charcoal (DCC) method whereas proliferative activity was measured by 3H-thymidine autoradiographic labeling index (LI). The percentages of ER+ and PgR+ cases resulted lower in IBC than in LABC (ER+, 44% versus 64%; PgR+, 30% versus 51%, respectively), pertaining to both premenopausal and postmenopausal women. Inflammatory breast carcinoma showed a higher median LI value than LABC (3.5% versus 1.6%; P = 0.006). Regarding clinical aspects, time to progression (TTP) in IBC patients was not affected by hormone receptor status (19 evaluable patients) or by LI (17 evaluable patients); PgR+ status and low LI resulted important for individualizing women with a longer median overall survival (OS). Inflammatory breast carcinoma has been verified to be a heterogeneous biological entity for which hormone receptors and cell kinetics could be useful in identifying patients with different prognoses and therefore candidates for a personalized therapy.
在两组分别患有炎性乳腺癌(IBC,28例患者)和局部晚期乳腺癌(LABC,50例患者)的患者中,研究了激素受体状态和增殖活性的生物学及预后作用。采用葡聚糖包被活性炭(DCC)法测定雌激素受体(ER)和孕激素受体(PgR),而通过3H-胸腺嘧啶核苷放射自显影标记指数(LI)测定增殖活性。ER+和PgR+病例的百分比在IBC中低于LABC(ER+,分别为44%对64%;PgR+,分别为30%对51%),这在绝经前和绝经后女性中均如此。炎性乳腺癌的LI中值高于LABC(3.5%对1.6%;P = 0.006)。关于临床方面,IBC患者的疾病进展时间(TTP)不受激素受体状态(19例可评估患者)或LI(17例可评估患者)的影响;PgR+状态和低LI对于确定中位总生存期(OS)较长的女性很重要。炎性乳腺癌已被证实是一种异质性生物学实体,激素受体和细胞动力学可用于识别具有不同预后的患者,从而作为个性化治疗的候选对象。